Bisphosphonates—the most widely used treatment for osteoporosis—are safe and effective, but are usually only given for ∼5 years followed by a drug holiday to reduce the risk of atypical femoral fractures
Denosumab is a potent antiresorptive, with an antifracture efficacy comparable to that of potent bisphosphonates; BMD changes with long-term use of denosumab seem to be more positive than those with bisphosphonates
Teriparatide—the most widely used anabolic agent—is well-tolerated and early concerns related to osteosarcoma have not been substantiated; effects of teriparatide on BMD are additive to those of antiresorptives
Strontium has marginal antifracture efficacy and its use is declining owing to concern about its cardiovascular safety profile
Cathepsin K inhibitors and sclerostin antibodies are anti-osteoporotic agents in development, which show great promise
Progress continues to be made in the development of therapeutics for fracture prevention. Bisphosphonates are now available orally and intravenously, often as inexpensive generics, and remain the most widely used interventions for osteoporosis. The major safety concern associated with the use of bisphosphonates is the development of femoral shaft stress fractures and, although rare, this adverse event affords the principal rationale for restricting bisphosphonate therapy to those individuals with femoral T-scores <−2.5, and for providing drug holidays in those individuals requiring therapy for >5 years. Newer antiresorptive therapies, in the form of denosumab and cathepsin K inhibitors, might increase efficacy and possibly circumvent some of the safety concerns associated with bisphosphonate use (for example, gastrointestinal and renal complications). The combination of teriparatide with antiresorptives markedly increases effects on BMD; new anabolic agents are also very promising in this regard. However, whether or not these changes in BMD translate into improved efficacy of fracture prevention remains to be determined. Vitamin D is important for the prevention of osteomalacia, but does not influence BMD or fracture risk in patients not deficient in vitamin D. The balance of risks and benefits of calcium supplementation is contentious, but patients should be encouraged to adhere to a balanced diet aimed at maintaining a healthy body weight. Consideration of a patient's risk of falling, and its mitigation, are also important. In this Review, I summarize the short-term and long-term effects of osteoporosis therapies.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Woodward, A. & Blakely, T. The Healthy Country? A History of Life and Death in New Zealand (Auckland University Press, 2014).
New Zealand Government. Statistics New Zealand [online], (2015).
Johnell, O. & Kanis, J. A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17, 1726–1733 (2006).
Kanis, J. A. et al. The components of excess mortality after hip fracture. Bone 32, 468–473 (2003).
Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C. & Khaltaev, N. The diagnosis of osteoporosis. J. Bone Miner. Res. 9, 1137–1141 (1994).
Dawson-Hughes, B. et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos. Int. 19, 449–458 (2008).
Henry, M. J., Pasco, J. A., Nicholson, G. C., Seeman, E. & Kotowicz, M. A. Prevalence of osteoporosis in Australian women: Geelong Osteoporosis Study. J. Clin. Densitom. 3, 261–268 (2000).
Jones, G. et al. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos. Int. 4, 277–282 (1994).
Kanis, J. A., Johnell, O., Oden, A., Johansson, H. & McCloskey, E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385–397 (2008).
Nguyen, N. D., Frost, S. A., Center, J. R., Eisman, J. A. & Nguyen, T. V. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos. Int. 19, 1431–1444 (2008).
McClung, M. R. et al. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 344, 333–340 (2001).
Jackson, R. D. et al. Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med. 354, 669–683 (2006).
Lewis, J. R., Zhu, K. & Prince, R. L. Adverse events from calcium supplementation: relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation. J. Bone Miner. Res. 27, 719–722 (2012).
Bolland, M. J., Grey, A., Avenell, A., Gamble, G. D. & Reid, I. R. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 342, d2040 (2011).
Reid, I. R. Efficacy, effectiveness and side effects of medications used to prevent fractures. J. Intern. Med. http://dx.doi.org/10.1111/joim.12339.
Lewis, J. R. et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. J. Bone Miner. Res. 30, 165–175 (2015).
Mao, P.-J. et al. Effect of calcium or vitamin D supplementation on vascular outcomes: a meta-analysis of randomized controlled trials. Int. J. Cardiol. 169, 106–111 (2013).
Larsen, E. R., Mosekilde, L. & Foldspang, A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J. Bone Miner. Res. 19, 370–378 (2004).
Bolland, M. J., Grey, A., Avenell, A. & Reid, I. R. Calcium supplements increase risk of myocardial infarction. J. Bone Miner. Res. 30, 389–390 (2015).
Reid, I. R., Bolland, M. J. & Grey, A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 383, 146–155 (2014).
Avenell, A., Gillespie, W. J., Gillespie, L. D. & O'Connell, D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD000227. http://dx.doi.org/10.1002/14651858.CD000227.pub3.
Chapuy, M. C. et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N. Engl. J. Med. 327, 1637–1642 (1992).
Reid, I. R. & Bolland, M. J. Calcium risk–benefit updated—new WHI analyses. Maturitas 77, 1–3 (2014).
Robbins, J. A. et al. Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy. Menopause 21, 116–123 (2014).
Abrahamsen, B. et al. Patient level pooled analysis of 68,500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 340, b5463 (2010).
Reid, I. R. & Bolland, M. J. Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues? Osteoporos. Int. 25, 2347–2357 (2014).
Russell, R. G., Watts, N. B., Ebetino, F. H. & Rogers, M. J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19, 733–759 (2008).
Black, D. M. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA 296, 2927–2938 (2006).
Schwartz, A. V. et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J. Bone Miner. Res. 25, 976–982 (2010).
Black, D. M. et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Miner. Res. 30, 934–944 (2015).
Cosman, F. et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J. Clin. Endocrinol. Metab. 99, 4546–4554 (2014).
Grey, A. et al. Five years of anti-resorptive activity after a single dose of zoledronate—results from a randomized double-blind placebo-controlled trial. Bone 50, 1389–1393 (2012).
Reid, I. R. et al. Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams. J. Clin. Endocrinol. Metab. 98, 557–563 (2013).
Langdahl, B. et al. Resolution of effects on bone turnover markers and bone mineral density after discontinuation of long-term bisphosphonate use [abstract]. J. Bone Miner. Res. 27 (Suppl. 1), S120 (2012).
Watts, N. B. et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos. Int. 19, 365–372 (2008).
Eastell, R., Hannon, R. A., Wenderoth, D., Rodriguez-Moreno, J. & Sawicki, A. Effect of stopping risedronate after long-term treatment on bone turnover. J. Clin. Endocrinol. Metab. 96, 3367–3373 (2011).
Bauer, D. C. et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern. Med. 174, 1126–1134 (2014).
Biswas, P. N., Wilton, L. V. & Shakir, S. A. Pharmacovigilance study of alendronate in England. Osteoporos. Int. 14, 507–514 (2003).
Reid, I. R., Gamble, G. D., Mesenbrink, P., Lakatos, P. & Black, D. M. Characterization of and risk factors for the acute-phase response after zoledronic acid. J. Clin. Endocrinol. Metab. 95, 4380–4387 (2010).
Reid, I. R. & Cornish, J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat. Rev. Rheumatol. 8, 90–96 (2012).
Cartsos, V. M., Zhu, S. & Zavras, A. I. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J. Am. Dent. Assoc. 139, 23–30 (2008).
Pazianas, M., Blumentals, W. A. & Miller, P. D. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos. Int. 19, 773–779 (2008).
Lin, T. C., Yang, C. Y., Kao Yang, Y. H. & Lin, S. J. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. Osteoporos. Int. 25, 1503–1511 (2014).
Assael, L. A. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J. Oral Maxillofac. Surg. 67, 35–43 (2009).
Manfredi, M., Merigo, E., Guidotti, R., Meleti, M. & Vescovi, P. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int. J. Oral Maxillofac. Surg. 40, 277–284 (2011).
Shane, E. et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 29, 1–23 (2014).
Schilcher, J., Koeppen, V., Aspenberg, P. & Michaëlsson, K. Risk of atypical femoral fracture during and after bisphosphonate use. N. Engl. J. Med. 371, 974–976 (2014).
Schilcher, J., Koeppen, V., Aspenberg, P. & Michaëlsson, K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 86, 100–107 (2015).
Dell, R. M. et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J. Bone Miner. Res. 27, 2544–2550 (2012).
Schilcher, J., Michaelsson, K. & Aspenberg, P. Bisphosphonate use and atypical fractures of the femoral shaft. N. Engl. J. Med. 364, 1728–1737 (2011).
Black, D. M. et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N. Engl. J. Med. 362, 1761–1771 (2010).
Meier, R. P., Perneger, T. V., Stern, R., Rizzoli, R. & Peter, R. E. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch. Intern. Med. 172, 930–936 (2012).
Lindsay, R., Hart, D. M., Forrest, C. & Baird, C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 2, 1151–1153 (1980).
Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321–333 (2002).
Anderson, G. L. et al. Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 291, 1701–1712 (2004).
Rossouw, J. E. et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297, 1465–1477 (2007).
Grese, T. A. et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl Acad. Sci. USA 94, 14105–14110 (1997).
Delmas, P. D. et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641–1647 (1997).
Reid, I. R. et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch. Intern. Med. 164, 871–879 (2004).
Ettinger, B. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282, 637–645 (1999).
Sharifi, M. & Lewiecki, E. M. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. Expert Rev. Clin. Pharmacol. 7, 281–291 (2014).
Mirkin, S., Ryan, K. A., Chandran, A. B. & Komm, B. S. Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms. Maturitas 77, 24–31 (2014).
Lindsay, R., Gallagher, J. C., Kagan, R., Pickar, J. H. & Constantine, G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil. Steril. 92, 1045–1052 (2009).
Rosen, C. J. (Ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 8th edn (American Society for Bone and Mineral Research, 2013).
Reid, I. R. et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J. Bone Miner. Res. 25, 2256–2265 (2010).
Miller, P. D. et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43, 222–229 (2008).
Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009).
Black, D. M. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809–1822 (2007).
Papapoulos, S. et al. Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extension [abstract]. J. Bone Miner. Res. 28 (Suppl. 1), S503 (2013).
Ferrari, S. et al. Further reduction in the nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the FREEDOM extension [abstract]. J. Bone Miner. Res. 28 (Suppl. 1), S6 (2013).
Black, D. M. et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Miner. Res. 27, 243–254 (2012).
Bone, H. G. et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350, 1189–1199 (2004).
Peddi, P., Lopez-Olivo, M. A., Pratt, G. F. & Suarez-Almazor, M. E. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat. Rev. 39, 97–104 (2013).
Geller, M. et al. Early findings from Prolia® post-marketing safety surveillance for atypical femoral fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis. Osteoporos Int. 25 (Suppl. 2), 56–57 (2014).
Reid, I. R., Pybus, J., Lim, T. M., Hannon, S. & Ibbertson, H. K. The assessment of intestinal calcium absorption using stable strontium. Calcif. Tissue Int. 38, 303–305 (1986).
Meunier, P. J. et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350, 459–468 (2004).
Reginster, J. Y. et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90, 2816–2822 (2005).
Recker, R. R. et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J. Bone Miner. Res. 24, 1358–1368 (2009).
Iolascon, G. et al. Osteoporosis drugs in real-world clinical practice: an analysis of persistence. Aging Clin. Exp. Res. 25, S137–S141 (2013).
Le Merlouette, M. et al. Strontium ranelate-induced DRESS syndrome. Ann. Dermatol. Venereol. 138, 124–128 (2011).
Tan, K. W., Wang, Y. S. & Tay, Y. K. Stevens–Johnson syndrome due to strontium ranelate. Ann. Acad. Med. Singapore 40, 510–511 (2011).
Medicines and Healthcare Products Regulatory Agency. Strontium ranelate (Protelos): risk of serious cardiac disorders—restricted indications, new contraindications, and warnings. Drug Safety Update 6, S1 (2013).
Bolland, M. J. & Grey, A. A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. BMJ Open 4, e005787 (2014).
Bolland, M. J. et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341, C3691 (2010).
Slovik, D. M. et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25 dihydroxyvitamin D. J. Bone Miner. Res. 1, 377–381 (1986).
Bilezikian, J. P. et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J. Clin. Endocrinol. Metab. 94, 335–339 (2009).
Arlot, M. et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J. Bone Miner. Res. 20, 1244–1253 (2005).
McClung, M. R. et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 165, 1762–1768 (2005).
Lindsay, R. et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350, 550–555 (1997).
Boonen, S. et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 93, 852–860 (2008).
Neer, R. M. et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001).
Lindsay, R. et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Intern. Med. 164, 2024–2030 (2004).
Greenspan, S. L. et al. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 146, 326–339 (2007).
Nakamura, T. et al. Randomized teriparatide human parathyroid hormone (PTH) 1–34 once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J. Clin. Endocrinol. Metab. 97, 3097–3106 (2012).
Hattersley, G. et al. Bone anabolic efficacy and safety of ba058, a novel analog of hPTHrP: 12-month extension data from a phase 2 clinical trial in postmenopausal women with osteoporosis. Bone Abstracts [online], (2013).
The Endocrine Society. Investigational osteoporosis drug, abaloparatide, lowers fracture risk. EurekAlert.org[online], (2015).
Black, D. M. et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349, 1207–1215 (2003).
Cosman, F. et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 503–511 (2011).
Leder, B. Z. et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J. Clin. Endocrinol. Metab. 99, 1694–1700 (2014).
Cosman, F. et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J. Clin. Endocrinol. Metab. 94, 3772–3780 (2009).
Vahle, J. L. et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol. Pathol. 32, 426–438 (2004).
Bang, U. C., Hyldstrup, L. & Jensen, J. E. The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos. Int. 25, 639–644 (2014).
Andrews, E. B. et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J. Bone Miner. Res. 27, 2429–2437 (2012).
Gauthier, J. Y. et al. The discovery of odanacatib (MK–0822), a selective inhibitor of cathepsin K. Bioorg. Med. Chem. Lett. 18, 923–928 (2008).
Bone, H. G. et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J. Bone Miner. Res. 25, 937–947 (2010).
Eisman, J. A. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J. Bone Miner. Res. 26, 242–251 (2011).
McClung, M. Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis. Results from the phase III long-term odanacatib fracture trial (LOFT). Presented at the 2014 Annual Meeting of the American Society for Bone and Mineral Research, Houston, TX.
Merck. Update on phase III trial for odanacatib, Merck's investigational cat-K inhibitor for osteoporosis. Mercknewsroom.com[online], (2012).
Ominsky, M. S. et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J. Bone Miner. Res. 26, 1012–1021 (2011).
Padhi, D., Jang, G., Stouch, B., Fang, L. A. & Posvar, E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19–26 (2011).
McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412–420 (2014).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
Murad, M. H. et al. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J. Clin. Endocrinol. Metab. 97, 1871–1880 (2012).
I.R.R. acknowledges support from the Health Research Council of New Zealand.
I.R.R. has received research grants or speaking and/or consulting fees from Amgen, Lilly, Merck, Novartis and Sanofi.
About this article
Cite this article
Reid, I. Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol 11, 418–428 (2015). https://doi.org/10.1038/nrendo.2015.71
Serum exosomes from young rats improve the reduced osteogenic differentiation of BMSCs in aged rats with osteoporosis after fatigue loading in vivo
Stem Cell Research & Therapy (2021)
Simulated effects of early menopausal bone mineral density preservation on long-term fracture risk: a feasibility study
Osteoporosis International (2021)
Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study
BMC Women's Health (2020)
Oviductus Ranae protein hydrolyzate prevents menopausal osteoporosis by regulating TGFβ/BMP2 signaling
Archives of Gynecology and Obstetrics (2019)
Substitutions of strontium in bioactive calcium silicate bone cements stimulate osteogenic differentiation in human mesenchymal stem cells
Journal of Materials Science: Materials in Medicine (2019)